BTAI
$1.73
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States.
Recent News
How The BioXcel Therapeutics (BTAI) Story Is Shifting With Dilution Risks And Funding Needs
The latest research update on BioXcel Therapeutics cuts the price target from US$10 to US$6, alongside a modest trim in the fair value estimate from $15.25 to $14.25. Bulls see this move as a recalibration that still leaves room for upside, while bears point to the lower target as a signal that equity dilution and funding needs are front and center. As you read on, you will see how these shifting views shape the evolving narrative around the stock and what to watch next. Stay updated as the...
1 Top Penny Stock to Watch Now
This small-cap biotech is chasing a big breakthrough in 2026.
What Analysts Think Is Changing The Story For BioXcel Therapeutics Now
BioXcel Therapeutics latest price target update keeps fair value steady at $16.75 per share, even as a slightly higher discount rate and largely unchanged ~455.2% revenue growth outlook underscore a more finely balanced risk reward profile. Analysts cite stronger visibility around long term revenue potential after the SERENITY At Home data, but also emphasize funding and execution uncertainties that limit how far the valuation can stretch for now. Read on to see how you can stay ahead of...
Looking at the Narrative for BioXcel Therapeutics After Fair Value Reset and Clinical Milestones
BioXcel Therapeutics has recently seen its Fair Value Estimate fall sharply, dropping from $23.75 to $16.75 per share. This shift comes as analysts weigh both encouraging clinical results and ongoing funding uncertainties for the company. Stay tuned to discover how these dynamics could affect the stock’s outlook and how you can keep informed as the narrative continues to evolve. Stay updated as the Fair Value for BioXcel Therapeutics shifts by adding it to your watchlist or portfolio...
BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates
BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of -41.56% and -34.67%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?